FASENRA (benralizumab) approved for eosinophilic granulomatosis with polyangiitis (EGPA)
This news item was issued on 8 April 2025 by Jill Smith, CEO of ASCIA, the peak professional body for clinical immunology and allergy in Australia and New Zealand.
ASCIA Members please log in to view.
FASENRA® (benralizumab) has recently been approved by the Therapeutic Goods Administration (TGA) for a new indication in Australian patients, with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).
EGPA is a rare form of necrotising vasculitis. It is characterised by the presence of asthma, nasal polyps and elevated eosinophils in the blood, lungs and other tissues which can lead to an ongoing inflammatory response resulting in organ damage. There is a high unmet need for targeted therapy in EGPA with current treatment characterised by long term, high-dose oral corticosteroid use.
FASENRA® is a monoclonal antibody that targets eosinophils, enabling the immune system to remove them.
AstraZeneca (suppliers of FASENRA®) have opened a Benralizumab EGPA Part-Pay Access Program, which can be acccessed by medical specialists for their patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).
The updated FASENRA® PI and indication for EGPA is available at https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2018-PI-01520-1
For medical information enquiries email